ZCL278

ZCL278 is a selective Cdc42 inhibitor with K_ds of 6.4 μM in fluorescence titration and 11.4 μM in surface plasmon resonance (SPR) measurement. ZCL278 is able to disrupt the Cdc42-ITSN interaction as well as GTP/GDP binding. ZCL278 has inhibitory effects on various enveloped viruses, but is ineffective against non-enveloped viruses. ZCL278 can be used for the studies of arsenic neurotoxicity and HER2-positive gastric cancer (GC)^[1][2][3][4]. IC50 & Target:Kd: 11.4 μM (Cdc42)^[1] In Vitro:ZCL278 (5-50 μM, 24 h) impedes wound healing without disruption of cell viability in PC-3 cells^[1].
ZCL278 (50 μM, 5-15 min) exhibits a time-dependent inhibition of Cdc42 activity in PC-3 cells^[1].
ZCL278 (50 μM, 0-10 min) inhibits mice primary neurons branchingand growthconemotility^[1].
ZCL278 (0.01-1000 μM, 0-18 h) does not interfere with Junin virus (JUNV) attachment to the cell surface or virus particle internalization into host cells, it prevents the release of JUNV ribonucleoprotein cores into the cytosol and decreases pH-mediated viral fusion with host membranes in Vero, SUM159, SVG-A, or A549 cells^[2].
ZCL278 (50 μM, 6-24 h) significantly inhibits VSV, LCMV and DV2 infections, but has no effect on non-enveloped virus PV1 in Vero or Huh7 cells^[2].
ZCL278 (20 μM, 25 h) improves the cytotoxicity of NaAsO₂ in rat astrocytes^[3].
ZCL278 reduces cholesterol levels in the plasma membrane and reverses collateral resistance between Trastuzumab (HY-P9907) and chemotherapy in TC cells^[4].
In Vivo:ZCL278 (1-100 μg/kg, i.p., once daily for 4 days) inhibits JUNV replication in a mouse model, and no toxicity is detected^[2].
ZCL278 (50 mg/kg, i.p., every four days for 33 days) effectively reduces cholesterol enrichment in the plasma membrane and reverses collateral resistance between Trastuzumab and chemotherapy in ^[4].